SEARCH

SEARCH BY CITATION

References

  • 1
    Bast RCJr,Feeney M,Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68: 1331-1337.
  • 2
    Yin BW,Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001; 20: 27371-27375.
  • 3
    Bast RCJr,Klug TL,St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309: 883-887.
  • 4
    Jacobs I,Bast RJJr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4: 1-12.
  • 5
    McGuire WP,Hoskins WJ,Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1-6.
  • 6
    Markman M,Bundy B,Alberts D, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1001-1007.
  • 7
    Muggia FM,Braly PS,Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000; 18: 106-115.
  • 8
    Rose PG,Nerenstone S,Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004; 351: 2489-2497.
  • 9
    Ozols RF,Bundy BN,Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194-3200.
  • 10
    Spriggs D,Brady MF,Rubin SC, et al. A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 449. Abstract 5004.
  • 11
    Armstrong DK,Bundy B,Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 34-43.
  • 12
    Hosmer D,Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons; 1999.
  • 13
    Talbot RW,Jacobsen DJ,Nagorney DM, et al. Temporary elevation after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet. 1989; 168: 407-412.
  • 14
    Markman M,Federico M,Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006; 103: 195-198.
  • 15
    Winter ME3rd,Maxwell GL,Tian C, et al. Gynecologic Oncology Study Group. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007; 24: 3621-3627.
  • 16
    Chan JK,Tian C,Monk BJ, et al. Gynecologic Oncology Group. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008; 112: 2202-2210.